ResMed (ASX:RMD) completed its acquisition of Noctrix Health, a medical device company developing clinically validated wearable therapeutics for chronic neurological disorders, according to a Tuesday statement by the company.
The acquisition broadens the company's clinical sleep health portfolio into an adjacent area with significant unmet need, focusing on the treatment of restless legs syndrome, the third most prevalent sleep disorder.
The deal includes Noctrix's US Food and Drug Administration de novo-cleared Nidra tonic motor activation therapy, a clinically validated treatment that reduces restless leg syndrome symptoms and improves sleep quality in patients unresponsive to drug therapies.
The company said the acquisition supports its 2030 strategy to scale connected home sleep and health solutions.